Blog

Quick Facts About PinatuzumabWhat is Pinatuzumab?Pinatuzumab is an antibody-drug conjugate (ADC) designed to target CD22, a protein highly expressed on B-cell malignancies, including non-Hodgkin lymphoma (NHL).What is the mechanism of action for Pinatuzumab?It delivers cytotoxic agents directly to cancer cells by binding to CD22, resulting in targeted cell death while sparing healthy tissues.What are the clinical applications of Pinatuzumab?Pinatuzumab has been explored in clinical trials for treating B-cell lymphomas and other hematologic malignancies.Is Pinatuzumab still in use?While specific trials have concluded, Pinatuzumab’s foundational research continues to inform ADC d …

Quick Facts About BelantamabWhat is Belantamab?Belantamab Mafodotin is a cutting-edge antibody-drug conjugate (ADC) designed for the treatment of relapsed or refractory multiple myeloma.How does Belantamab work?It targets B-cell maturation antigen (BCMA) on multiple myeloma cells, delivering a potent cytotoxic agent to destroy cancerous cells effectively.What are the side effects of Belantamab?Keratopathy (eye toxicity) is the most notable adverse effect, requiring regular ophthalmic monitoring during treatment.Is Belantamab approved?Yes, Belantamab Mafodotin received accelerated approval from the FDA for patients with limited treatment options for multiple myeloma.1.) Understa …

Quick Facts About GirentuximabWhat is Girentuximab?Girentuximab is a monoclonal antibody targeting carbonic anhydrase IX (CAIX), predominantly expressed in renal cell carcinoma (RCC) cells. It is designed to enhance tumor-specific immune responses.What is the mechanism of action for Girentuximab?Girentuximab binds to CAIX on RCC cells, promoting antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), crucial for its therapeutic efficacy.What are the clinical applications of Girentuximab?It has shown promise in treating advanced RCC and is being explored in combination with radioisotopes for precision oncology.1.) Understanding GirentuximabGi …